Evaluating the impact of glucokinase activation on risk of cardiovascular disease: a Mendelian randomisation analysis

Glucokinase activators (GKAs) are an emerging class of glucose lowering drugs that activate the glucose-sensing enzyme glucokinase (GK). Pending formal cardiovascular outcome trials, we applied two-sample Mendelian randomisation (MR) to investigate the impact of GK activation on risk of cardiovascul...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular diabetology 2022-09, Vol.21 (1), p.192-192, Article 192
Main Authors: Wang, Ke, Shi, Mai, Huang, Chuiguo, Fan, Baoqi, Luk, Andrea O Y, Kong, Alice P S, Ma, Ronald C W, Chan, Juliana C N, Chow, Elaine
Format: Article
Language:English
Subjects:
Asian people
Biobanks
Cardiovascular disease
Cardiovascular diseases
Cardiovascular Diseases - diagnosis
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - genetics
Chemoreception
Clinical trials
Congestive heart failure
Consortia
Coronary artery
Diabetes
Drug dosages
Enzymes
Genetic diversity
Genome-wide association studies
Genome-Wide Association Study
Genomes
Glucagon
Glucokinase
Glucokinase - genetics
Glucokinase activator
Glucose
Glucose - pharmacology
Heart diseases
Heart failure
Humans
Insulin
Mendelian randomisation
Mendelian Randomization Analysis
Mutation
Peptides
Sensitivity analysis
Statistical analysis
Statistical significance
Stroke
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glucokinase activators (GKAs) are an emerging class of glucose lowering drugs that activate the glucose-sensing enzyme glucokinase (GK). Pending formal cardiovascular outcome trials, we applied two-sample Mendelian randomisation (MR) to investigate the impact of GK activation on risk of cardiovascular diseases. We used independent genetic variants in or around the glucokinase gene meanwhile associated with HbA at genome-wide significance (P 
ISSN:1475-2840
1475-2840
DOI:10.1186/s12933-022-01613-6